Clinical Trials Directory

Trials / Completed

CompletedNCT00831454

Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

Relationship of Polymorphisms and Mutations of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors Responsiveness in Non-small-cell Lung Cancer Patients

Status
Completed
Phase
Study type
Observational
Enrollment
51 (actual)
Sponsor
Armando Santoro, MD · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.

Detailed description

DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.

Conditions

Timeline

Start date
2008-09-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2009-01-29
Last updated
2014-12-02

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT00831454. Inclusion in this directory is not an endorsement.